{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T14:32:04Z","timestamp":1786717924664,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J App Basic Med Res"],"published-print":{"date-parts":[[2016]]},"DOI":"10.4103\/2229-516x.192587","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T00:39:08Z","timestamp":1476923948000},"page":"245","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of thyroid disorders in hepatitis C virus positive patients on interferon and antiviral therapy"],"prefix":"10.4103","volume":"6","author":[{"given":"Gitanjali","family":"Goyal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KMDS","family":"Panag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravinder","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-516X.192587-1","first-page":"27","volume-title":"Australia's Notifiable Diseases Status, 2002 Annual Report of the National Notifiable Diseases Surveillance System","author":"Yohannes","year":"2004","journal-title":"CDI"},{"key":"key-10.4103\/2229-516X.192587-2","first-page":"1","volume-title":"Centers for Disease Control and Prevention","author":"Recommendations","year":"1998","journal-title":"MMWR Recomm Rep"},{"key":"key-10.4103\/2229-516X.192587-3","first-page":"556","volume-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-516X.192587-4","unstructured":"Sievert W. An overview of antiviral therapy for chronic hepatitis C infection. In: Crofts N, Dore G, Locarnini S, editor. Hepatitis C: An Australian Perspective. Melbourne: IP Communications; 2001. p. 140-54."},{"key":"key-10.4103\/2229-516X.192587-5","first-page":"61","volume-title":"Syndromes and complications of interferon therapy","author":"Borg","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"key-10.4103\/2229-516X.192587-6","first-page":"1051","volume-title":"Interferon alpha treatment and thyroid dysfunction","author":"Tomer","year":"2007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key-10.4103\/2229-516X.192587-7","first-page":"2489","volume-title":"Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons","author":"Pfeffer","year":"1998","journal-title":"Cancer Res"},{"key":"key-10.4103\/2229-516X.192587-8","first-page":"431","volume-title":"Interferons: Mechanisms of action and clinical applications","author":"Parmar","year":"2003","journal-title":"Curr Opin Oncol"},{"key":"key-10.4103\/2229-516X.192587-9","first-page":"34","volume-title":"Interferon in oncological practice: Review of interferon biology, clinical applications, and toxicities","author":"Jonasch","year":"2001","journal-title":"Oncologist"},{"key":"key-10.4103\/2229-516X.192587-10","doi-asserted-by":"crossref","unstructured":"Baron S, Tyring SK, Fleischmann WR Jr., Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA 1991;266:1375-83.","DOI":"10.1001\/jama.1991.03470100067035"},{"key":"key-10.4103\/2229-516X.192587-11","first-page":"975","volume-title":", et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-516X.192587-12","first-page":"1711","volume-title":"Side effects of therapy for chronic hepatitis C","author":"Russo","year":"2003","journal-title":"Gastroenterology"},{"key":"key-10.4103\/2229-516X.192587-13","first-page":"563","volume-title":"Thyroid disorders in chronic hepatitis C virus infection","author":"Antonelli","year":"2006","journal-title":"Thyroid"},{"key":"key-10.4103\/2229-516X.192587-14","first-page":"958","volume-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"key-10.4103\/2229-516X.192587-15","first-page":"1445","volume-title":"Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy","author":"Fernandez-Soto","year":"1998","journal-title":"Arch Intern Med"},{"key":"key-10.4103\/2229-516X.192587-16","first-page":"1929","volume-title":"Increased level of interferon-alpha in blood of patients with insulin-dependent diabetes mellitus: Relationship with coxsackievirus B infection","author":"Chehadeh","year":"2000","journal-title":"J Infect Dis"},{"key":"key-10.4103\/2229-516X.192587-17","first-page":"661","volume-title":"The clinical and physiological spectrum of interferon-alpha induced thyroiditis: Toward a new classification","author":"Mandac","year":"2006","journal-title":"Hepatology"},{"key":"key-10.4103\/2229-516X.192587-18","first-page":"864315","volume-title":"Association of interferon-alpha and ribavirin-induced thyroid dysfunction with severity of disease and response to treatment in Pakistani Asian patients of chronic hepatitis C","author":"Nadeem","year":"2012","journal-title":"Hepat Res Treat"},{"key":"key-10.4103\/2229-516X.192587-19","first-page":"e55364","volume-title":"Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: A systematic review based analysis","author":"Nair","year":"2013","journal-title":"PLoS One"}],"container-title":["International Journal of Applied and Basic Medical Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:29:19Z","timestamp":1786714159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2229-516X.192587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016]]}},"alternative-id":["192587"],"URL":"https:\/\/doi.org\/10.4103\/2229-516x.192587","relation":{},"ISSN":["2229-516X"],"issn-type":[{"value":"2229-516X","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]}}}